TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)
Brief Summary: RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating in women with breast cancer who have already received 5 years of aromatase inhibitor therapy.

PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating women with primary breast cancer who have received 5 years of aromatase inhibitor therapy.


Options:
A: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR
B: Arm Label: controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: cases; Type: EXPERIMENTAL; Interventions: Behavioral: mindfulness based stress reduction (MBSR) | Intervention Type: BEHAVIORAL; Name: mindfulness based stress reduction (MBSR); Assigned to Arm(s): cases
C: Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Trial of Depression Care Management by Electronic Secure Messaging
Brief Summary: This study will test whether an electronic system that monitors and sends messages to help people with depression could be feasible, acceptable, and potentially effective as a treatment.


Options:
A: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Depression care management by secure messaging | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression care management by secure messaging; Assigned to Arm(s): 1
C: Arm Label: PND-MCI; Type: EXPERIMENTAL; Interventions: Other: multi-component intervention | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multi-component intervention; Assigned to Arm(s): PND-MCI | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
D: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Trial of Depression Care Management by Electronic Secure Messaging
Brief Summary: This study will test whether an electronic system that monitors and sends messages to help people with depression could be feasible, acceptable, and potentially effective as a treatment.


Options:
A: Arm Label: Adherence counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling | Arm Label: Alarm device; Type: ACTIVE_COMPARATOR; Interventions: Device: Alarm device | Arm Label: Counseling and alarm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling, Device: Alarm device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adherence counseling; Assigned to Arm(s): Adherence counseling, Counseling and alarm | Intervention Type: DEVICE; Name: Alarm device; Assigned to Arm(s): Alarm device, Counseling and alarm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Depression care management by secure messaging | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression care management by secure messaging; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: In Home Health Messaging Device | Intervention Type: BEHAVIORAL; Name: In Home Health Messaging Device; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee
Brief Summary: The purpose of this study is to determine if the traditional Chinese herbal compound (Huo-Luo-Xiao-Ling Dan, or HLXL) is effective in treating OA of the knee in addition to participants current OA of the knee treatment(s) and also to determine the best dosage of HLXL that is safe and well tolerated.


Options:
A: Arm Label: Huo-Luo-Xiao-Ling; Type: ACTIVE_COMPARATOR; Interventions: Drug: HLXL | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: HLXL | Intervention Type: DRUG; Name: HLXL; Assigned to Arm(s): Huo-Luo-Xiao-Ling, Placebo
B: Intervention Type: DRUG; Name: Glucosamine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: acetaminophen extended release | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: acetaminophen extended release; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 002
D: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis
Brief Summary: The current study is initiated in order to assess the impact of a PD solution containing L-carnitine on insulin sensitivity measured by a hyperinsulinemic euglycemic clamp.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-Carnitine | Intervention Type: DRUG; Name: L-Carnitine; Assigned to Arm(s): 1
B: Arm Label: Glucose solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: PD solution containing glucose | Arm Label: Glucose and L-carnitine solution; Type: EXPERIMENTAL; Interventions: Drug: PD solution containing glucose and L-carnitine | Intervention Type: DRUG; Name: PD solution containing glucose; Assigned to Arm(s): Glucose solution | Intervention Type: DRUG; Name: PD solution containing glucose and L-carnitine; Assigned to Arm(s): Glucose and L-carnitine solution
C: Arm Label: placebo; Type: OTHER; Interventions: Drug: placebo | Arm Label: L-carnitine; Type: OTHER; Interventions: Drug: L-carnitine | Intervention Type: DRUG; Name: L-carnitine; Assigned to Arm(s): L-carnitine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Oral nutritional supplement with probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Oral nutritional supplement with probiotics | Arm Label: Oral nutritional supplement without probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Oral nutritional supplement without probiotics | Arm Label: Individualized dietary recommendations; Type: ACTIVE_COMPARATOR; Interventions: Other: Dietary recommendations | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral nutritional supplement with probiotics; Assigned to Arm(s): Oral nutritional supplement with probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral nutritional supplement without probiotics; Assigned to Arm(s): Oral nutritional supplement without probiotics | Intervention Type: OTHER; Name: Dietary recommendations; Assigned to Arm(s): Individualized dietary recommendations

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures
Brief Summary: The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib is beneficial for the use in fibromyalgia. We intend to seek whether this medication may improve psychiatric and rheumatologic parameters of the disease.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
B: Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etoricoxib | Intervention Type: DRUG; Name: etoricoxib; Assigned to Arm(s): A
C: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway
Brief Summary: The purpose of this study is to delineate the effects of preoperative oral carbohydrate on immediate postoperative insulin resistance (PIR) in patients undergoing elective open colorectal cancer resection, and to further clarify the hypotheses that preoperative oral carbohydrate treatment attenuates PIR in patients by enhancing insulin signaling to PI3K-dependent pathway.


Options:
A: Arm Label: Fasting; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fasting. | Arm Label: Water administration; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Water administration | Arm Label: carbohydrate drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: carbohydrate drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Water administration; Assigned to Arm(s): Water administration | Intervention Type: DIETARY_SUPPLEMENT; Name: carbohydrate drink; Assigned to Arm(s): carbohydrate drink | Intervention Type: BEHAVIORAL; Name: Fasting.; Assigned to Arm(s): Fasting
B: Arm Label: OCH; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative Oral Carbohydrate | Arm Label: FSD; Type: NO_INTERVENTION; Interventions: Dietary Supplement: Preoperative Oral Carbohydrate | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative Oral Carbohydrate; Assigned to Arm(s): OCH | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative Oral Carbohydrate; Assigned to Arm(s): FSD
C: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test
D: Arm Label: water; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: whey protein plus carbohydrate drink | Arm Label: whey protein plus carbohydrate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: whey protein plus carbohydrate drink | Intervention Type: DIETARY_SUPPLEMENT; Name: whey protein plus carbohydrate drink; Assigned to Arm(s): water, whey protein plus carbohydrate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas
Brief Summary: This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.


Options:
A: Arm Label: A (PGL4001 5mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: PGL4001 matching placebo and iron | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): A (PGL4001 5mg) | Intervention Type: DRUG; Name: PGL4001 matching placebo and iron; Assigned to Arm(s): C (placebo) | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): B (PGL4001 10mg)
B: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mifegyne | Intervention Type: DRUG; Name: Mifegyne; Assigned to Arm(s): I | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas
Brief Summary: This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.


Options:
A: Arm Label: A (PGL4001 5mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: PGL4001 matching placebo and iron | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): A (PGL4001 5mg) | Intervention Type: DRUG; Name: PGL4001 matching placebo and iron; Assigned to Arm(s): C (placebo) | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): B (PGL4001 10mg)
B: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)
C: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Adding Montelukast Sodium 10 mg Per Day to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma
Brief Summary: The purpose of this study is to evaluate the effectiveness of adding Montelukast Sodium (singulair®) 10 mg per day to inhaled corticosteroids in adult subjects with uncontrolled asthma.


Options:
A: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
B: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study
Brief Summary: Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to

1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure)
2. quality of life (2. outcome measure)
3. live birth rate (2. outcome measure)
4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and
5. number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures).

In addition to the above mentioned efficacy outcome measures the safety outcome measure "frequency of known side-effects" will be compared between the two protocols.


Options:
A: Arm Label: Flare Up; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flare up | Arm Label: Microdose GnRh; Type: EXPERIMENTAL; Interventions: Drug: Microdose GnRh | Intervention Type: DRUG; Name: Microdose GnRh; Assigned to Arm(s): Microdose GnRh | Intervention Type: DRUG; Name: Flare up; Assigned to Arm(s): Flare Up
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Patients receiving short protocol IVF/ICSI-treatment. | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Long protocol | Intervention Type: DRUG; Name: Patients receiving short protocol IVF/ICSI-treatment.; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Long protocol; Assigned to Arm(s): 2
C: Arm Label: CONSORT Dosing; Type: EXPERIMENTAL; Interventions: Drug: GONAL f® prefilled pen | Arm Label: Standard Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: GONAL f® prefilled pen | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): CONSORT Dosing | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): Standard Dosing
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Intervention Type: DRUG; Name: Follitropin Delta (FE 999049); Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Follitropin Alfa (GONAL-F); Assigned to Arm(s): B, D

Answer: B